Hemab Therapeutics/X
Aug 13, 2025, 09:21
VELORA Discover Study Now Enrolling: Advancing Care for Type 1 Von Willebrand Disease
Hemab Therapeutics shared an inviting post on X:
”Now enrolling people living with Type 1 Von Willebrand disease (VWD) into the VELORA Discover study.
This observational study aims to deepen understanding of Type 1 VWD and help lay the groundwork for future advances in care.
If you are living with Type 1 VWD or treating people who are, learn more about how to participate.”
You can direct your inquiries to [email protected].
Stay informed on all opportunities in the field of bleeding disorders with Hemostasis Today.
-
Jan 4, 2026, 17:02Oğuzhan Işılay on Stabilizing Human Blood Clotting Factor VIII
-
Jan 4, 2026, 16:48Sleep Apnea: Full Breakdown from John Chuback
-
Jan 4, 2026, 16:36Edwin Ofori Atta on Permissive Hypertension For Ischemic Stroke
-
Jan 4, 2026, 16:27Nasrin Haghani on The Milli-Spinners: Breakthrough Technology Transforming Stroke Clot Removal
-
Jan 4, 2026, 16:10Godfrey Gandawa on Neuroplasticity in Stroke Rehabilitation
-
Jan 4, 2026, 14:53What Do Blood and Plasma Donors Think About Biobanking? A New Study Reveals Their Attitudes
-
Jan 4, 2026, 14:51First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries
-
Jan 4, 2026, 14:51Shreya Agrawal: Top 5 Practical Hematology Lessons from 2025 – Mild Cytopenias are Rarely “Incidental” and More
-
Jan 4, 2026, 14:46We Analyzed Data From the Start of the COVID-19 Pandemic to 2024 – What Did We find?